PD-1 inhibitor (sintilimab) and fruquintinib plus SOX as conversion therapy for initially unresectable gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): Updated results from a single-arm, phase 2 clinical trial.

Details

Language :

English

ISSN :

0732183X

Volume :

43

Database :

Supplemental Index

Journal :

Journal of Clinical Oncology

Publication Type :

Academic Journal

Accession number :

182479100

Full Text :

https://doi.org/10.1200/JCO.2025.43.4_suppl.406